Term,Abbreviation,Category,Plain-language definition,Formal/technical definition,Example/Notes,Primary sources/references,Source URL
HGVS notation,HGVS,Nomenclature,A standard way to write genetic changes so everyone reads them the same.,"Human Genome Variation Society (HGVS) nomenclature system for describing sequence variants at the genomic (g.), coding DNA (c.), non-coding RNA (n.), mitochondrial (m.), RNA (r.) and protein (p.) levels.",c.1582G>A (p.Gly528Asp); g.17:43045729C>T; p.Trp24Ter.,HGVS; RefSeq; Ensembl,https://varnomen.hgvs.org/
Genomic notation,g.,Nomenclature,Variant written as a chromosome coordinate.,"HGVS level designator 'g.' for genomic sequences; coordinates referenced to a genome assembly (e.g., GRCh37/GRCh38).",g.43045729C>T on chr17 (GRCh38).,HGVS; UCSC; Ensembl,https://varnomen.hgvs.org/
Coding DNA notation,c.,Nomenclature,Variant written relative to a transcript’s coding sequence.,HGVS 'c.' designator; positions counted from the A of the ATG start codon as c.1.,c.76A>T; c.1582G>A.,HGVS; RefSeq; MANE,https://varnomen.hgvs.org/
Protein notation,p.,Nomenclature,Variant written as the protein change it causes.,"HGVS 'p.' notation using amino acid codes to denote changes (missense, nonsense, frameshift, etc.).",p.Gly12Asp; p.Trp24Ter; p.Val600Glu.,HGVS,https://varnomen.hgvs.org/
Mitochondrial notation,m.,Nomenclature,Variant written relative to the mitochondrial genome.,HGVS 'm.' designator for mitochondrial genome positions.,m.3243A>G (MT-TL1).,HGVS; MITOMAP,https://varnomen.hgvs.org/; https://www.mitomap.org/
Reference SNP ID,rsID,Identifier,A unique rs-number that identifies a variant in dbSNP.,dbSNP Reference SNP cluster ID that aggregates submissions representing the same variant.,rs429358 in APOE.,dbSNP,https://www.ncbi.nlm.nih.gov/snp/
ClinVar Allele ID,CAid,Identifier,Stable ID for a ClinVar allele record.,ClinVar allele accession representing a unique submitted allele record (independent of interpretations).,CA123456789.,ClinVar,https://www.ncbi.nlm.nih.gov/clinvar/
ClinVar Variation ID,VCV,Identifier,ClinVar’s variation record ID that holds clinical assertions.,VCV identifier references ClinVar variation archive entries containing clinical interpretations and evidence.,VCV000012345.,ClinVar,https://www.ncbi.nlm.nih.gov/clinvar/
MANE Select transcript,MANE,Transcript resource,The agreed 'main' transcript to use for clinical reporting.,Matched Annotation from NCBI and EMBL-EBI: MANE Select is a single representative transcript per gene harmonized between RefSeq and Ensembl.,BRCA1 MANE Select: NM_007294.4 = ENST00000357654.9.,MANE (NCBI/Ensembl),https://www.ncbi.nlm.nih.gov/refseq/MANE/
MANE Plus Clinical,MANE Plus,Transcript resource,Additional clinically relevant transcripts beyond the Select one.,MANE Plus Clinical includes extra transcripts important for clinical reporting for some genes with multiple clinically significant isoforms.,"Genes with multiple clinically used transcripts (e.g., TTN).",MANE (NCBI/Ensembl),https://www.ncbi.nlm.nih.gov/refseq/MANE/
HGNC gene symbol,HGNC,Identifier,Official short name for a gene.,HUGO Gene Nomenclature Committee assigns unique gene symbols and names to human genes.,"BRCA1, CFTR.",HGNC,https://www.genenames.org/
Genome build,GRCh37/38,Reference,Which human genome version coordinates refer to.,"Reference genome assembly versions used as positional references (GRCh37/hg19, GRCh38/hg38).",chr17:43044295-43125482 (GRCh38).,Genome Reference Consortium; UCSC; Ensembl,https://www.ncbi.nlm.nih.gov/grc
Cytoband,,Reference,Chromosomal location label seen under a microscope.,Giemsa-staining based chromosome region notation such as 17q21.31.,BRCA1 at 17q21.31.,ISCN; UCSC,https://genome.ucsc.edu/
Missense variant,,Variant type,A DNA change that swaps one amino acid for another.,Single nucleotide variant altering a codon such that a different amino acid is encoded.,c.35G>A → p.Gly12Asp.,Sequence Ontology; ACMG/AMP,https://www.sequenceontology.org/
Synonymous (silent) variant,,Variant type,A DNA change that does not change the amino acid.,"Codon change that leaves the encoded amino acid unchanged (often assumed neutral, but can affect splicing/regulation).",c.354G>A → p.Gly118Gly.,Sequence Ontology,https://www.sequenceontology.org/
Nonsense variant,Stop gained,Variant type,"A DNA change that creates a stop signal, truncating the protein.",SNV that introduces a premature termination codon (PTC).,p.Trp24Ter (p.W24*).,Sequence Ontology; ACMG/AMP,https://www.sequenceontology.org/
Frameshift variant,fs,Variant type,"Insertion/deletion that shifts the reading frame, usually breaking the protein.",Indel not in multiples of three nucleotides causing downstream codon re-interpretation and often PTC/NMD.,c.100_101del → p.Ser34Valfs*12.,Sequence Ontology; ACMG/AMP,https://www.sequenceontology.org/
In-frame indel,,Variant type,Bases added/removed in multiples of three so reading frame stays intact.,"Insertion/deletion of nucleotides that preserves codon frame, altering protein length by amino acids rather than shifting frame.",c.90_92del → p.Lys31del.,Sequence Ontology,https://www.sequenceontology.org/
Splice-site variant,,Variant type,Change at intron–exon borders that may change RNA splicing.,"Variant affecting canonical splice donor (±1/2) or acceptor (±1/2) sites, potentially causing exon skipping or cryptic splice use.",c.92+1G>T; c.93-2A>G.,ClinVar; ACMG/AMP,https://www.ncbi.nlm.nih.gov/clinvar/
Splice region variant,,Variant type,Change near splice sites that may alter splicing.,Variant within near-splice intronic/exonic regions that can influence splice efficiency or create new splice sites (commonly ±3–8 intronic or exonic −3/+5).,c.93-8A>G.,Sequence Ontology,https://www.sequenceontology.org/
Start-loss variant,,Variant type,"Change that disrupts the start codon, possibly blocking translation initiation.",Variant affecting the canonical ATG initiation codon (c.1) leading to uncertain translation from downstream ATG.,c.1A>G (p.Met1?).,HGVS; Sequence Ontology,https://varnomen.hgvs.org/
Stop-loss variant,,Variant type,"Change that removes the natural stop codon, lengthening the protein.","Variant converting a stop codon into a sense codon, producing protein extension until next stop codon.",p.*200Glnext*45.,HGVS; Sequence Ontology,https://varnomen.hgvs.org/
Copy number variant,CNV,Variant type,A big chunk of DNA is deleted or duplicated.,"Structural variant altering copy number of genomic segments, typically >50 bp, often kb–Mb.",Heterozygous deletion of exon 7.,ClinGen; dbVar; ISCN,https://www.ncbi.nlm.nih.gov/dbvar
Structural variant,SV,Variant type,Large DNA change in structure or position of segments.,"Genomic alterations >50 bp including deletions, duplications, inversions, translocations, insertions, mobile element insertions, repeat expansions.",Balanced translocation t(9;22).,dbVar; ClinGen; ISCN,https://www.ncbi.nlm.nih.gov/dbvar
Mobile element insertion,MEI,Variant type,Insertion of transposable elements like Alu/LINE into DNA.,Insertion events of transposable elements that may disrupt genes or regulation.,Alu insertion in BRCA2 intron.,dbVar; literature,https://www.ncbi.nlm.nih.gov/dbvar
Short tandem repeat,STR,Variant type,Short DNA sequences repeated many times; expansions can cause disease.,Microsatellite repeats (1–6 bp) whose expanded lengths beyond thresholds cause disorders.,HTT CAG expansion in Huntington disease.,GeneReviews; OMIM,https://www.omim.org/
Repeat expansion,,Variant type,Disease from too many repeats.,"Pathogenic increase in short tandem repeat count above normal range causing disease via gain-of-function, toxic RNA/protein, or loss of expression.",FMR1 CGG >200 (Fragile X syndrome).,GeneReviews; OMIM,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Allele frequency,AF/MAF,Population genetics,How often a variant occurs in a population.,Proportion of chromosomes carrying an allele in a defined population; minor allele frequency (MAF) is the less common allele frequency.,gnomAD AF = 0.0003 (0.03%).,gnomAD; 1000 Genomes,https://gnomad.broadinstitute.org/
Allele count,AC,Population metric,How many alternate alleles were observed in a dataset.,Number of alternate allele observations across all samples in a dataset.,"AC = 5 in a dataset of 10,000 chromosomes.",VCF spec; gnomAD,https://samtools.github.io/hts-specs/VCFv4.2.pdf
Allele number,AN,Population metric,Total chromosomes assessed (denominator for AF).,Total number of chromosomes at the locus considered (2N for diploids minus missing genotypes).,"AN = 20000 for 10,000 diploid samples.",VCF spec; gnomAD,https://samtools.github.io/hts-specs/VCFv4.2.pdf
Variant allele fraction,VAF/AB,Sequencing metric,What fraction of DNA reads carry the variant.,"Proportion of sequencing reads supporting the alternate allele; ~50% expected for germline heterozygous, ~100% for homozygous, lower for mosaic/somatic.",VAF 0.48 suggests heterozygous germline.,GATK docs; lab manuals,https://gatk.broadinstitute.org/
Zygosity,,Genetics,Whether the two copies of a gene are the same or different.,"Homozygous (both alleles same), heterozygous (two different alleles), hemizygous (one copy in sex chromosomes).",Heterozygous c.35G>A.,Genetics textbooks,https://www.ncbi.nlm.nih.gov/books/NBK22270/
Mode of inheritance,MOI,Genetics,How a condition is passed through families.,"Pattern of transmission including autosomal dominant, autosomal recessive, X-linked, mitochondrial, digenic, polygenic/multifactorial.",Autosomal recessive for cystic fibrosis.,OMIM; GeneReviews,https://www.omim.org/
Penetrance,,Genetic concept,How many people with a change actually get the disease.,"Probability that individuals with a genotype will manifest the phenotype, often age-dependent.",BRCA1 carriage: age-dependent penetrance for breast cancer (~45–70% lifetime).,GeneReviews; OMIM,https://www.omim.org/
Expressivity,,Genetic concept,How strongly or differently a disease appears in different people with the same variant.,Variation in signs or severity among individuals with the same genotype.,Neurofibromatosis 1 shows variable expressivity (skin findings to tumors).,GeneReviews; OMIM,https://www.omim.org/
Haploinsufficiency,,Genetic concept,When having only one working copy of a gene isn't enough.,When loss-of-function (LOF) of one allele causes disease because the remaining allele cannot supply sufficient function.,Some developmental disorder genes are haploinsufficient.,ClinGen Dosage Sensitivity,https://clinicalgenome.org/
Triplosensitivity,,Genetic concept,Having an extra copy of a gene causes disease.,Increased dosage due to duplication/triplication leads to phenotype in dosage-sensitive genes.,Certain gene duplications cause neurodevelopmental disorders.,ClinGen Dosage Sensitivity,https://clinicalgenome.org/
Compound heterozygosity,,Genetic concept,Two different variants on two gene copies cause recessive disease.,Presence of two distinct pathogenic alleles in trans in the same gene leading to disease in recessive conditions.,CFTR: c.1521_1523delCTT and p.Gly551Asp in trans.,GeneReviews,https://www.ncbi.nlm.nih.gov/books/NBK1116/
De novo variant,DNV,Genetic concept,A new variant present in the patient but not in parents.,Variant arising in the germline or early embryo; not found in parental DNA testing.,Trio testing finds variant absent in both parents.,GeneReviews; ClinGen,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Mosaicism,,Genetic concept,Not all cells have the same DNA change in a person.,Presence of two or more genetically distinct cell populations derived from a single zygote; variant allele fraction often <50% depending on tissue and timing.,Post-zygotic variant with VAF ~10% in blood.,GeneReviews; OMIM,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Founder variant,,Population genetics,A variant common in a group because ancestors carried it.,Allele with elevated frequency in a population due to founder effect and genetic drift.,BRCA1 c.68_69delAG in Ashkenazi Jews.,GeneReviews; literature,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Term,Abbreviation,Category,Plain-language definition,Formal/technical definition,Example/Notes,Primary sources/references,Source URL
Pathogenic,P,Classification,Strong evidence the variant causes disease.,ACMG/AMP clinical significance category indicating sufficient evidence that the variant is disease-causing.,ClinVar: Pathogenic annotation for a variant in BRCA1.,ACMG/AMP 2015; ClinVar,https://www.acmg.net/; https://www.ncbi.nlm.nih.gov/clinvar/
Likely pathogenic,LP,Classification,High chance the variant causes disease.,ACMG/AMP category indicating >90% probability of pathogenicity based on aggregated evidence.,Often used when multiple supportive lines of evidence exist but not definitive.,ACMG/AMP 2015,https://www.acmg.net/
Variant of uncertain significance,VUS,Classification,Not enough evidence to say whether the variant is harmful or not.,"ACMG/AMP category assigned when data are insufficient, conflicting, or absent to reach benign/pathogenic.",Common interim classification for novel variants in new genes.,ACMG/AMP 2015; ClinVar,https://www.acmg.net/; https://www.ncbi.nlm.nih.gov/clinvar/
Likely benign,LB,Classification,Probably not disease-causing.,"ACMG/AMP category indicating strong evidence for benign impact, but not definitive.",Used when multiple benign criteria are met.,ACMG/AMP 2015,https://www.acmg.net/
Benign,B,Classification,Strong evidence the variant is not harmful.,ACMG/AMP clinical significance category supporting non-pathogenic status.,High-frequency population polymorphisms often classified benign.,ACMG/AMP 2015,https://www.acmg.net/
ACMG/AMP guidelines,,Framework,Standard rules to classify genetic variants clinically.,"2015 joint standards and guidelines with evidence codes (PVS1, PS, PM, PP, BS, BP, BA) to combine evidence into classifications.",PVS1 for loss-of-function in LOF genes; PM2 for rarity in population databases.,ACMG/AMP 2015; ClinGen,https://www.acmg.net/
PVS1,,ACMG Evidence Code,Very strong evidence for pathogenicity if variant causes loss of function in a gene where LOF is disease mechanism.,"Null variants (nonsense, frameshift, canonical ±1/2 splice site, initiation codon, exon deletion) in genes where LOF is established mechanism. Strength can be moderated by gene-specific rules.",p.Trp24Ter in a LOF gene with established haploinsufficiency.,ACMG/AMP 2015; ClinGen SVI,https://www.acmg.net/; https://clinicalgenome.org/
PS1,,ACMG Evidence Code,Strong evidence: the variant causes same amino acid change as a known pathogenic variant but via a different DNA change.,Same protein change as previously established pathogenic variant (different codon/nucleotide change).,Different nucleotide causing p.Arg117His where p.Arg117His is known pathogenic.,ACMG/AMP 2015,https://www.acmg.net/
PS2,,ACMG Evidence Code,Strong evidence from confirmed de novo occurrence.,"Variant confirmed de novo (in affected with no family history) with parental relationships verified (e.g., by testing).",Trio confirming variant absent in both parents for a dominant disease.,ACMG/AMP 2015,https://www.acmg.net/
PS3,,ACMG Evidence Code,Strong evidence from functional studies demonstrating a damaging effect.,Well-established in vitro/in vivo functional studies supporting damaging effect on gene/protein.,Cellular assay showing loss of protein function.,ACMG/AMP 2015,https://www.acmg.net/
PS4,,ACMG Evidence Code,Strong evidence if variant is significantly more common in affected individuals vs controls.,Statistically significant enrichment of variant in cases versus controls.,Observed in multiple unrelated affected patients compared with population controls.,ACMG/AMP 2015,https://www.acmg.net/
PM1,,ACMG Evidence Code,Moderate evidence: variant in mutational hotspot or critical domain without benign variation.,Located in well-established functional domain or hotspot essential for protein function.,Variant in kinase domain hotspot known for activating mutations.,ACMG/AMP 2015,https://www.acmg.net/
PM2,,ACMG Evidence Code,Moderate evidence from rarity or absence in population databases.,Absent or extremely rare in controls for a disorder with full penetrance at early age.,Not observed in gnomAD or below disease-specific threshold.,ACMG/AMP 2015; gnomAD,https://gnomad.broadinstitute.org/
PM3,,ACMG Evidence Code,Moderate evidence when variant is observed in trans with pathogenic variant for recessive disorders.,Detection in trans with a known pathogenic variant supports pathogenicity in recessive disease.,Compound heterozygous configuration with pathogenic allele in trans.,ACMG/AMP 2015,https://www.acmg.net/
PM4,,ACMG Evidence Code,Moderate evidence: protein length changes due to in-frame indels or stop-loss.,In-frame indels or stop-loss in non-repeat regions that alter protein length.,In-frame deletion removing critical residues in functional domain.,ACMG/AMP 2015,https://www.acmg.net/
PM5,,ACMG Evidence Code,Moderate evidence for a novel missense at a residue where other missense changes are pathogenic.,Novel missense at residue with known pathogenic missense variant(s).,Missense at same amino acid position as known pathogenic variant.,ACMG/AMP 2015,https://www.acmg.net/
PP1,,ACMG Evidence Code,Supporting evidence from cosegregation with disease in families.,Variant showing segregation with disease in multiple affected relatives.,Observed in multiple affected relatives consistent with inheritance pattern.,ACMG/AMP 2015; ClinGen SVI,https://www.acmg.net/; https://clinicalgenome.org/
PP3,,ACMG Evidence Code,Supporting evidence from multiple computational predictors suggesting deleterious effect.,"Computational predictions for deleteriousness (conservation, splicing, structural impact) across multiple tools.",High CADD and deleterious SIFT/PolyPhen predictions for missense.,ACMG/AMP 2015,https://www.acmg.net/
BP1,,ACMG Evidence Code,Supporting benign evidence when missense change occurs in gene where only truncating variants cause disease.,Missense substitution in gene where LOF is main mechanism; missense less likely to be pathogenic.,Missense in a haploinsufficient gene primarily impacted by truncating variants.,ACMG/AMP 2015,https://www.acmg.net/
BS1,,ACMG Evidence Code,Strong benign evidence when allele frequency is too high for a rare disease.,Allele frequency greater than expected for disorder prevalence and penetrance supporting benign classification.,Common variant frequency in gnomAD above disease threshold (BA1/BS1 criteria).,ACMG/AMP 2015; gnomAD,https://gnomad.broadinstitute.org/
BS2,,ACMG Evidence Code,Strong benign evidence if variant observed in healthy adults inconsistent with disease.,Observed in unaffected older individuals or in trans with pathogenic allele for a fully penetrant dominant condition.,Seen in unaffected older adult population samples.,ACMG/AMP 2015,https://www.acmg.net/
BP4,,ACMG Evidence Code,Supporting benign evidence when computational tools predict no impact.,Multiple computational tools predict no deleterious effect on gene/protein.,Benign predictions across SIFT/PolyPhen/CADD below thresholds.,ACMG/AMP 2015,https://www.acmg.net/
Population frequency criterion,BA1/BS1/PM2,ACMG Evidence,Using how common a variant is to evaluate pathogenicity/benignity.,BA1 (stand-alone benign) and BS1 (strong benign) indicate frequency high enough to be inconsistent with rare disease; PM2 indicates absent/rare in controls supporting pathogenic.,BA1 = too common; PM2 = absent/rare.,ACMG/AMP 2015; ClinGen SVI,https://www.acmg.net/; https://gnomad.broadinstitute.org/
ClinVar,,Database,Public archive of clinical variant interpretations and supporting evidence.,"NIH database aggregating submissions on variants, clinical significance annotations, and supporting evidence with review status.",Entries labelled Pathogenic/BENIGN/VUS with submitter evidence and review stars.,ClinVar,https://www.ncbi.nlm.nih.gov/clinvar/
gnomAD,,Database,Large population reference giving variant frequencies and constraint metrics.,"Genome Aggregation Database of exomes/genomes providing allele frequencies across populations and gene constraint metrics (LOEUF, pLI legacy).","AF, AC, AN, LOEUF values per gene.",gnomAD,https://gnomad.broadinstitute.org/
OMIM,,Database,Curated catalog linking genes to human phenotypes.,Online Mendelian Inheritance in Man: authoritative compendium of human genes and genetic phenotypes with MIM numbers and clinical summaries.,"OMIM entries for gene–disease relationships, e.g., BRCA1 MIM.",OMIM,https://www.omim.org/
GeneReviews,,Resource,"Clinical, peer-reviewed summaries on genetic conditions and counseling.","Expert-authored chapters covering diagnosis, management, genetics, and counseling for inherited disorders.",GeneReviews chapters often used for counseling and management guidance.,GeneReviews (NCBI Bookshelf),https://www.ncbi.nlm.nih.gov/books/NBK1116/
dbSNP,,Database,Public catalog of small variants with rsIDs.,NCBI resource for single nucleotide polymorphisms and small indels; rsIDs used widely in literature and databases.,rsIDs such as rs429358.,dbSNP,https://www.ncbi.nlm.nih.gov/snp/
dbVar,,Database,Public database of structural variants/CNVs.,NCBI database for large genomic variants and structural variant records.,dbVar accessions for large deletions/duplications.,dbVar,https://www.ncbi.nlm.nih.gov/dbvar/
DECIPHER,,Database,Clinical database linking CNVs/SVs to phenotypes for rare disorders.,Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl resources.,Used to match patient CNVs to reported cases with phenotype.,DECIPHER (Sanger),https://decipher.sanger.ac.uk/
LOVD,,Database,Locus-specific variant databases curated per gene/group.,Leiden Open Variation Database hosts gene-centric variant submissions with literature curation.,Gene-specific curated variant lists for some clinical labs or research groups.,LOVD,https://databases.lovd.nl/
HGMD (commercial),,Database,Human Gene Mutation Database: literature-curated disease-causing variants (subscription).,Commercially curated resource of published disease-associated variants with literature references.,Used in research and clinical annotation where licensed.,HGMD,http://www.hgmd.cf.ac.uk/
Ensembl VEP,VEP,Tool,Tool that annotates variant consequences across transcripts and databases.,"Ensembl Variant Effect Predictor annotates consequences, transcript impacts, population frequency annotations, and in silico predictions.","Outputs predicted consequence (missense, stop_gained) per transcript.",Ensembl VEP,https://www.ensembl.org/info/docs/tools/vep/index.html
ANNOVAR,,Tool,"Command-line tool to annotate variants with gene, population and functional data.","Functional annotation tool that adds gene-based, region-based and filter-based annotations from multiple databases.","Used to annotate VCFs with gnomAD, ClinVar, dbSNP, etc.",ANNOVAR,https://annovar.openbioinformatics.org/
SnpEff,,Tool,Program that predicts variant impact on genes/transcripts.,Annotation tool predicting effect (high/moderate/low) and consequence types on various transcripts.,Classifies variant impact categories for VCF files.,SnpEff,http://snpeff.sourceforge.net/
SIFT,,Predictor,Tool that predicts whether an amino acid change affects protein function.,Sequence-homology based predictor scoring missense variants; scores <0.05 often considered deleterious.,SIFT score 0.02 → predicted damaging.,SIFT,https://sift.bii.a-star.edu.sg/
PolyPhen-2,,Predictor,Tool that predicts if a missense change is likely damaging.,Uses sequence/structure features to categorize missense as benign/possibly/probably damaging.,PolyPhen-2: probably damaging for some missense.,PolyPhen-2,http://genetics.bwh.harvard.edu/pph2/
CADD,,Predictor,Combined score reflecting variant deleteriousness across annotations.,Combined Annotation Dependent Depletion (CADD) integrates multiple annotations into a PHRED-like score; higher indicates greater predicted deleteriousness.,CADD PHRED ≥20 often considered potentially damaging.,CADD,https://cadd.gs.washington.edu/
REVEL,,Predictor,Ensemble score for missense pathogenicity from many tools.,Meta-predictor combining multiple missense prediction tools producing score 0–1 (higher = more likely pathogenic).,REVEL score 0.7 suggests likely deleterious for missense.,REVEL,https://sites.google.com/site/revelgenomics/
SpliceAI,,Predictor,Deep learning model predicting splice impact of variants.,Estimates probability and position for splice gain/loss due to variants; Δ score closer to 1 indicates stronger predicted splice effect.,SpliceAI Δ ≥0.5 often considered significant for splicing impact.,SpliceAI,https://github.com/Illumina/SpliceAI
pLI,,Constraint metric,Legacy measure of a gene’s intolerance to loss-of-function variants.,Probability of being loss-of-function intolerant (ExAC legacy); pLI ≥0.9 indicates LOF intolerance.,Used historically to prioritize LOF variants in constrained genes.,ExAC (legacy),http://exac.broadinstitute.org/
LOEUF,,Constraint metric,Updated gnomAD metric measuring LOF intolerance.,Loss-of-function observed/expected upper bound fraction (LOEUF); lower values indicate stronger constraint.,LOEUF 0.2 suggests high intolerance to LOF.,gnomAD,https://gnomad.broadinstitute.org/
Missense Z-score,,Constraint metric,Z-score showing intolerance of a gene to missense variation.,Higher positive Z-score indicates stronger depletion of missense variation relative to expectation.,High Z-score suggests missense-constrained gene for which missense variants may be more significant.,gnomAD,https://gnomad.broadinstitute.org/
ClinGen,,Consortium,"Group that curates gene–disease validity, dosage sensitivity, and provides curation resources.",Clinical Genome Resource developing expert curation and resources for variant and gene-disease interpretation.,"ClinGen gene–disease validity categories, dosage sensitivity maps.",ClinGen,https://clinicalgenome.org/
ClinGen gene–disease validity,,Curation,How strongly a gene is linked to a disease.,"ClinGen framework classifies gene–disease associations as Definitive, Strong, Moderate, Limited, Disputed, Refuted, or No Known Disease Relationship.",Used to trust variant interpretation in given gene for clinical use.,ClinGen,https://clinicalgenome.org/
ClinGen Dosage Sensitivity,,Curation,Curation of genes for haploinsufficiency and triplosensitivity.,ClinGen assigns haploinsufficiency (HI) and triplosensitivity (TS) scores (0–3) indicating strength of evidence for dosage sensitivity.,HI score 3 = sufficient evidence of haploinsufficiency causing disease.,ClinGen Dosage,https://clinicalgenome.org/curation-support/dosage-sensitivity-curation/
Term,Abbreviation,Category,Plain-language definition,Formal/technical definition,Example/Notes,Primary sources/references,Source URL
Whole-exome sequencing,WES,Testing,Sequencing just the protein-coding parts of genes.,High-throughput sequencing of captured exonic regions to detect SNVs/indels in coding sequence and splice junctions.,Typical mean depth 80–150× for exomes; may miss CNVs and non-coding variants.,GeneReviews; lab manuals,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Whole-genome sequencing,WGS,Testing,"Sequencing nearly the entire genome, coding and noncoding.",Shotgun sequencing of genomic DNA providing base-level coverage of coding and noncoding regions and improved structural variant detection vs WES.,Better for SVs and non-coding variants; larger data volume/cost.,GeneReviews; lab manuals,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Targeted gene panel,,Testing,Sequencing a selected set of genes related to a phenotype.,"NGS limited to curated gene list for a given disease domain (e.g., cardiomyopathy panel).",Faster and cheaper than WES for focused questions; limited scope.,Lab test catalogs; GeneReviews,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Sanger sequencing,,Testing,High-accuracy method to read a short DNA segment.,Dideoxy chain-termination sequencing (gold-standard) used to confirm NGS variants and to sequence small regions.,Used frequently to validate NGS calls or test specific variants.,Lab manuals,https://www.ncbi.nlm.nih.gov/books/NBK27445/
MLPA,,Testing,Method to detect exon-level deletions/duplications.,Multiplex Ligation-dependent Probe Amplification measures relative copy number of exons for specific genes.,"Common for detecting single-exon deletions/duplications (e.g., DMD, SMN1).",MRC-Holland; lab manuals,https://www.mrc-holland.com/
qPCR,,Testing,Quantifies DNA to infer copy number or expression.,Quantitative PCR used for CNV confirmation or gene expression assays.,Used to validate CNV calls from arrays or NGS.,Lab manuals,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1350996/
Coverage (depth),DP,QC metric,How many sequencing reads cover a base.,Number of reads overlapping a genomic locus; higher depth generally increases confidence in variant calls.,Exome may aim for mean 100×; clinical pipelines require coverage thresholds per region.,GATK docs; lab manuals,https://gatk.broadinstitute.org/
Genotype quality,GQ,QC metric,Confidence score in the genotype call.,Phred-scaled probability that the genotype is incorrect; higher GQ indicates higher confidence.,GQ ≥20 often considered acceptable for germline.,GATK docs,https://gatk.broadinstitute.org/
Quality score,QUAL,QC metric,Confidence score that a variant exists at the site.,Phred-scaled confidence in the variant call itself.,Used in VCF fields for variant filtering.,VCF spec,https://samtools.github.io/hts-specs/VCFv4.2.pdf
Limit of detection,LoD,Clinical lab,Smallest variant level a test can reliably detect.,Lowest VAF or smallest copy change detectable with specified sensitivity/specificity; important for somatic assays.,Somatic panels LoD often ~2–5% VAF.,CAP/CLIA; lab manuals,https://www.cap.org/
Reportable range,,Clinical lab,Parts of the genome a test is validated to detect and report.,Validated genomic regions where analytical performance meets required thresholds and results can be reported clinically.,Exome reportable range may exclude poorly covered exons.,CAP/CLIA guidelines,https://www.cap.org/
Phasing,,Genetics,Whether two variants are on the same chromosome (cis) or opposite ones (trans).,"Determination of cis vs trans configuration via parental testing, read-backed phasing, or long reads; relevant for compound het interpretation.",Compound het requires trans for recessive disease.,GeneReviews; lab manuals,https://www.ncbi.nlm.nih.gov/books/NBK1116/
Cis/Trans,,Genetics,Cis means same chromosome; trans means opposite chromosomes.,Relative arrangement of alleles/haplotypes affecting interpretation (cis may not produce recessive disease if both variants on same allele).,Two variants in cis on same chromosome vs trans on opposite chromosomes.,Genetics texts,https://www.ncbi.nlm.nih.gov/books/NBK22270/
Segregation analysis,,Clinical genetics,Checking if a variant tracks with disease in a family.,Statistical and qualitative co-segregation analysis to support pathogenicity (PP1/BS4 criteria).,Strong segregation supports pathogenicity; lack of segregation supports benignity.,ACMG/AMP; ClinGen SVI,https://www.acmg.net/
Nonsense-mediated decay,NMD,Molecular,Cell process that removes mRNAs with early stops to prevent truncated protein.,Eukaryotic surveillance pathway degrading transcripts with premature termination codons typically >50–55 nt upstream of last exon–exon junction.,NMD may influence whether PTC causes LOF vs escape leads to truncated protein with gain/loss effects.,Molecular biology texts,https://www.ncbi.nlm.nih.gov/books/NBK6052/
Gene–disease validity,,Curation,Strength of evidence a gene causes a disease.,"ClinGen framework with categories: Definitive, Strong, Moderate, Limited, Disputed, Refuted, No Known Disease Relationship.",Used for confidence in interpreting variants in the gene for a given phenotype.,ClinGen,https://clinicalgenome.org/
Actionability,,Curation,"Whether a genetic result can guide prevention, treatment, or management.","ClinGen and other resources assess clinical actionability including severity, likelihood, and effectiveness of interventions.",ACMG secondary findings list elements are considered actionable.,ClinGen; ACMG,https://clinicalgenome.org/; https://www.acmg.net/
ACMG secondary findings list,,Guidance,Genes/variants recommended for opportunistic reporting when found incidentally because they are actionable.,ACMG periodically publishes list of genes where pathogenic variants should be reported if identified in clinical sequencing regardless of testing indication.,ACMG SF v3.1 (example update cycle).,ACMG,https://www.acmg.net/
ClinVar star rating,,Metadata,How much review/support backs a ClinVar assertion.,"ClinVar review status stars indicate review level: one submitter, multiple submitters, expert panel, practice guideline, etc.",★ (single submitter) to ★★★★ (practice guideline/expert panel).,ClinVar,https://www.ncbi.nlm.nih.gov/clinvar/
Non-invasive prenatal testing,NIPT / cfDNA,Prenatal screening,A maternal blood test that screens fetal chromosomes using fetal DNA in the mother's blood.,Analysis of cell-free fetal DNA (cffDNA) in maternal plasma to screen for common aneuploidies (trisomy 21/18/13) and some microdeletions; screening not diagnostic.,High sensitivity/specificity for T21; positive results should be confirmed with diagnostic testing (CVS/amniocentesis).,ACOG; ISPD; ClinGen,https://www.acog.org/; https://www.ispdhome.org/
Chorionic villus sampling,CVS,Prenatal diagnostic,Sampling placenta tissue to test fetal DNA earlier in pregnancy.,"Invasive prenatal diagnostic procedure to obtain chorionic villi for cytogenetic or molecular testing, typically ~10–13+6 weeks.",Provides diagnostic result for chromosomal and many single-gene conditions.,GeneReviews; ACOG,https://www.acog.org/
Amniocentesis,,Prenatal diagnostic,Sampling amniotic fluid around the fetus to test fetal DNA.,"Invasive diagnostic procedure, usually performed after 15 weeks, to obtain amniotic fluid for karyotype, microarray or molecular tests.",Gold-standard diagnostic testing for aneuploidy and many genetic diagnoses.,GeneReviews; ACOG,https://www.acog.org/
First-trimester combined screen,,Prenatal screening,Ultrasound + blood markers to estimate risk for Down syndrome in early pregnancy.,NT ultrasound combined with maternal serum markers (PAPP-A and free β-hCG) at 11–13+6 weeks to provide a risk estimate for trisomy 21 and 18; positive screens prompt counseling and further testing.,"Screening, not diagnostic.",ACOG; ISPD,https://www.acog.org/
Quad screen,,Prenatal screening,Second-trimester blood test measuring four proteins to estimate risk of certain fetal conditions.,"Measures AFP, hCG, estriol (uE3), and inhibin-A in second trimester to assess risk for neural tube defects and aneuploidies; less specific than NIPT for common aneuploidies.",Screen result should be followed by counseling/testing if high risk.,ACOG,https://www.acog.org/
Fetal fraction,,Prenatal metric,Portion of fetal DNA in the mother’s blood sample used for NIPT.,Percentage of cell-free DNA in maternal plasma derived from placenta (fetal) — low fetal fraction reduces NIPT accuracy; thresholds depend on platform.,Typical minimum ~4% fetal fraction required for valid NIPT result on many platforms.,ISPD; ACOG,https://www.ispdhome.org/; https://www.acog.org/
Nuchal translucency,NT,Prenatal ultrasound,Ultrasound measure of fluid at the back of a fetus’s neck; higher values can indicate chromosome problems.,First-trimester ultrasound measurement used in risk assessment for aneuploidy and structural defects.,Increased NT may prompt further genetic testing and fetal echocardiography.,ACOG; GeneReviews,https://www.acog.org/
ACMG/AMP somatic guidelines,,Somatic framework,Guidelines to classify tumor variants for clinical actionability.,AMP/ASCO/CAP joint consensus tiering for somatic variants classifying therapeutic/diagnostic/prognostic significance (Tier I–IV).,"Tier I variants have strong clinical significance (e.g., EGFR L858R in lung cancer).",AMP/ASCO/CAP,https://www.cap.org/
Tumor mutational burden,TMB,Cancer biomarker,How many mutations are present per megabase in tumor DNA.,Number of somatic mutations per megabase used as a biomarker for immunotherapy response; thresholds vary by assay and tumor type.,High TMB may predict response to checkpoint inhibitors in some cancers.,Cancer genomics literature; guidelines,https://www.cancer.gov/
Microsatellite instability,MSI,Cancer biomarker,Many errors in repetitive DNA due to mismatch repair defects.,MSI-High status indicates deficiency in mismatch repair (MMR) and can indicate Lynch syndrome or predict immunotherapy response.,Detected by PCR or NGS; MSI-High tumors may be Lynch syndrome–associated.,NCCN; literature,https://www.nccn.org/
Variant allele frequency (somatic),VAF,Somatic metric,Fraction of tumor DNA supporting the variant.,"Proportion of reads supporting variant in tumor sample; influenced by tumor purity, clonality, ploidy.",VAF 0.12 could reflect a subclonal mutation or low tumor purity.,Cancer genomics texts,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319964/
EGFR, ,Oncology biomarker,EGFR mutations can predict response to certain lung cancer drugs.,"Epidermal growth factor receptor activating mutations (e.g., exon 19 deletions, p.L858R) are actionable targets for EGFR TKIs in NSCLC.",EGFR exon 19del; p.L858R are common actionable variants.,NCCN; ClinVar,https://www.nccn.org/
ALK, ,Oncology biomarker,ALK gene fusions can respond to ALK inhibitors.,"Anaplastic lymphoma kinase fusions (e.g., EML4-ALK) in NSCLC confer sensitivity to ALK-targeted therapies.",EML4-ALK fusion.,NCCN; ClinVar,https://www.nccn.org/
BRAF V600E,,Oncology biomarker,BRAF V600E mutation is targetable in melanoma and other cancers.,BRAF p.Val600Glu activating mutation targeted by BRAF/MEK inhibitor therapy in melanoma and other tumor types.,p.Val600Glu (V600E).,NCCN; ClinVar,https://www.nccn.org/
KRAS,,Oncology biomarker,KRAS mutations affect prognosis and therapy choices in several cancers.,"Activating KRAS mutations (e.g., G12C) are important for targeted therapy decisions and may confer resistance to some targeted agents.",p.Gly12Cys (G12C).,NCCN; ClinVar,https://www.nccn.org/
PD-L1,CD274,Oncology biomarker,PD-L1 expression helps decide immunotherapy use in certain cancers.,Protein expression of PD-L1 by IHC used as companion diagnostic for checkpoint inhibitors in several tumor types.,PD-L1 TPS ≥50% in some NSCLC contexts guides therapy.,NCCN; FDA,https://www.nccn.org/
RefSeq,,Reference,NCBI curated sequences for genes and transcripts.,Reference Sequence database with NM_/NR_ transcript and NP_ protein accessions used in clinical reporting.,NM_000492.4 (CFTR).,RefSeq (NCBI),https://www.ncbi.nlm.nih.gov/refseq/
Ensembl,,Reference,Genome annotation resource with ENSG/ENST IDs.,"EMBL-EBI genome annotation platform providing gene, transcript, and variant annotation.",ENSG00000012048 (BRCA1).,Ensembl,https://www.ensembl.org/
Canonical transcript,,Transcript,Database- or community-selected main transcript for a gene.,Transcript selected as representative by annotation pipelines or community standards; MANE Select harmonizes between RefSeq and Ensembl.,MANE Select identifies canonical clinical transcript for reporting.,Ensembl; NCBI MANE,https://www.ncbi.nlm.nih.gov/refseq/MANE/
HPO, ,Ontology,Standard vocabulary for describing patient features.,Human Phenotype Ontology provides coded phenotype terms (HP: numbers) for clinical annotation and computational matching.,HP:0001250 (Seizure).,HPO; Monarch Initiative,https://hpo.jax.org/
Orphanet,,Database,Portal for rare diseases and orphan drugs and their gene relationships.,"Structured resource on rare diseases, prevalence, and gene associations for clinical and research use.",Used for rare disease annotation and information.,Orphanet,https://www.orpha.net/
DECIPHER,,Database,Database linking CNVs and genomic disorders to phenotype.,Database of chromosomal imbalance and phenotype in humans using Ensembl resources to aid interpretation of rare CNVs.,Used for phenotype-driven CNV interpretation.,DECIPHER,https://decipher.sanger.ac.uk/
Reporting disclaimers,,Clinical governance,Phrases to include in chatbot responses noting limits of the tool.,"Examples: 'This information is educational only and not a substitute for professional medical advice. For diagnosis, please consult a certified genetic counselor or clinical geneticist.'","Chatbot must include limits, referral suggestions, and escalation prompts for urgent or high-stakes queries.",ACMG/clinic policies; institutional protocols,https://www.acmg.net/